was read the article
array:25 [ "pii" => "S201325141730127X" "issn" => "20132514" "doi" => "10.1016/j.nefroe.2017.02.011" "estado" => "S300" "fechaPublicacion" => "2017-07-01" "aid" => "366" "copyright" => "Sociedad Española de Nefrología" "copyrightAnyo" => "2017" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2017;37:406-14" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4114 "formatos" => array:3 [ "EPUB" => 353 "HTML" => 3031 "PDF" => 730 ] ] "Traduccion" => array:1 [ "es" => array:20 [ "pii" => "S0211699517300723" "issn" => "02116995" "doi" => "10.1016/j.nefro.2017.02.008" "estado" => "S300" "fechaPublicacion" => "2017-07-01" "aid" => "366" "copyright" => "Sociedad Española de Nefrología" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2017;37:406-14" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 7369 "formatos" => array:3 [ "EPUB" => 379 "HTML" => 6033 "PDF" => 957 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Enfermedad renal crónica en individuos hipertensos ≥60 años atendidos en Atención Primaria" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "406" "paginaFinal" => "414" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Chronic kidney disease in hypertensive subjects ≥60 years treated in Primary Care" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figura 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1217 "Ancho" => 1638 "Tamanyo" => 95338 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Estimación, a partir del modelo de regresión logística, de la probabilidad de estar en el grupo de filtrado glomerular inferior a 60 años según edad y sexo, en la muestra seleccionada de individuos hipertensos ≥ 60 años de la base de datos <span class="elsevierStyleItalic">SIDIAP plus</span> a 1 enero de 2011 (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>73.730).</p> <p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Estimación en individuos no fumadores con cociente albúmina/creatinina <30<span class="elsevierStyleHsp" style=""></span>mg/dL, sin dislipidemia, obesidad, fibrilación auricular, insuficiencia cardíaca, ni diabetes, de entorno urbano y en el quintil central del indicador MEDEA de nivel socioeconómico. Para cualquier otro perfil de individuo las probabilidades esperadas por el modelo de regresión logística difieren a las mostradas; sin embargo, el efecto de la interacción edad-sexo mostrado se mantiene.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Betlem Salvador-González, Jordi Mestre-Ferrer, Maria Soler-Vila, Luisa Pascual-Benito, Eva Alonso-Bes, Oriol Cunillera-Puértolas" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Betlem" "apellidos" => "Salvador-González" ] 1 => array:2 [ "nombre" => "Jordi" "apellidos" => "Mestre-Ferrer" ] 2 => array:2 [ "nombre" => "Maria" "apellidos" => "Soler-Vila" ] 3 => array:2 [ "nombre" => "Luisa" "apellidos" => "Pascual-Benito" ] 4 => array:2 [ "nombre" => "Eva" "apellidos" => "Alonso-Bes" ] 5 => array:2 [ "nombre" => "Oriol" "apellidos" => "Cunillera-Puértolas" ] 6 => array:1 [ "colaborador" => "en representación del grupo de investigación del proyecto MARREC-HTA" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S201325141730127X" "doi" => "10.1016/j.nefroe.2017.02.011" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S201325141730127X?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699517300723?idApp=UINPBA000064" "url" => "/02116995/0000003700000004/v1_201707260022/S0211699517300723/v1_201707260022/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2013251417301189" "issn" => "20132514" "doi" => "10.1016/j.nefroe.2017.06.008" "estado" => "S300" "fechaPublicacion" => "2017-07-01" "aid" => "345" "copyright" => "Sociedad Española de Nefrología" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2017;37:415-22" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2896 "formatos" => array:3 [ "EPUB" => 288 "HTML" => 2104 "PDF" => 504 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Intermediate steroid withdrawal after renal transplantation and anti-HLA antibodies (HLA-Abs) development" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "415" "paginaFinal" => "422" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Retirada intermedia de esteroides después del trasplante renal y desarrollo de anticuerpos anti-HLA (Ac-antiHLA)" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1411 "Ancho" => 1745 "Tamanyo" => 109159 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Comparison of graft survival in both groups. Group I: steroids withdrawal, Group II: steroids maintenance. Log rank: <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.432.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Elena Monfá, David San Segundo, Juan Carlos Ruiz San Millán, Judith Sanabria, Zoila Albines, Emilio Rodrigo, Iñigo Romón, Esther Asensio, Manuel Arias, Marcos López-Hoyos" "autores" => array:10 [ 0 => array:2 [ "nombre" => "Elena" "apellidos" => "Monfá" ] 1 => array:2 [ "nombre" => "David" "apellidos" => "San Segundo" ] 2 => array:2 [ "nombre" => "Juan Carlos Ruiz" "apellidos" => "San Millán" ] 3 => array:2 [ "nombre" => "Judith" "apellidos" => "Sanabria" ] 4 => array:2 [ "nombre" => "Zoila" "apellidos" => "Albines" ] 5 => array:2 [ "nombre" => "Emilio" "apellidos" => "Rodrigo" ] 6 => array:2 [ "nombre" => "Iñigo" "apellidos" => "Romón" ] 7 => array:2 [ "nombre" => "Esther" "apellidos" => "Asensio" ] 8 => array:2 [ "nombre" => "Manuel" "apellidos" => "Arias" ] 9 => array:2 [ "nombre" => "Marcos" "apellidos" => "López-Hoyos" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251417301189?idApp=UINPBA000064" "url" => "/20132514/0000003700000004/v1_201708310023/S2013251417301189/v1_201708310023/en/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S2013251417301050" "issn" => "20132514" "doi" => "10.1016/j.nefroe.2017.05.008" "estado" => "S300" "fechaPublicacion" => "2017-07-01" "aid" => "321" "copyright" => "Sociedad Española de Nefrología" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2017;37:397-405" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3398 "formatos" => array:3 [ "EPUB" => 296 "HTML" => 2567 "PDF" => 535 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Increase of allosensitization after a kidney graft failure: Predictors and effect on retransplantation outcomes" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "397" "paginaFinal" => "405" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Aumento de la alosensibilización después de un fallo del injerto renal: predictores y efecto en los resultados del retrasplante" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1486 "Ancho" => 1616 "Tamanyo" => 56115 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">PRA levels (%) before 1st and 2nd kidney transplant. Median values are shown. Boxes display the interquartile range of the values; whiskers display the lowest and the highest value within 1.5 times below or above the interquartile range, respectively. PARA, panel reactive antibody; KT, kidney transplant.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Andreia Campos, Jorge Malheiro, Sandra Tafulo, Sofia Santos, Leonídeo Dias, La Salete Martins, Manuela Almeida, Sofia Pedroso, A. Castro Henriques, António Cabrita" "autores" => array:10 [ 0 => array:2 [ "nombre" => "Andreia" "apellidos" => "Campos" ] 1 => array:2 [ "nombre" => "Jorge" "apellidos" => "Malheiro" ] 2 => array:2 [ "nombre" => "Sandra" "apellidos" => "Tafulo" ] 3 => array:2 [ "nombre" => "Sofia" "apellidos" => "Santos" ] 4 => array:2 [ "nombre" => "Leonídeo" "apellidos" => "Dias" ] 5 => array:2 [ "nombre" => "La Salete" "apellidos" => "Martins" ] 6 => array:2 [ "nombre" => "Manuela" "apellidos" => "Almeida" ] 7 => array:2 [ "nombre" => "Sofia" "apellidos" => "Pedroso" ] 8 => array:2 [ "nombre" => "A. Castro" "apellidos" => "Henriques" ] 9 => array:2 [ "nombre" => "António" "apellidos" => "Cabrita" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S0211699517300024" "doi" => "10.1016/j.nefro.2016.11.020" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699517300024?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251417301050?idApp=UINPBA000064" "url" => "/20132514/0000003700000004/v1_201708310023/S2013251417301050/v1_201708310023/en/main.assets" ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Chronic kidney disease in hypertensive subjects ≥60 years treated in Primary Care" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "406" "paginaFinal" => "414" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Betlem Salvador-González, Jordi Mestre-Ferrer, Maria Soler-Vila, Luisa Pascual-Benito, Eva Alonso-Bes, Oriol Cunillera-Puértolas" "autores" => array:7 [ 0 => array:4 [ "nombre" => "Betlem" "apellidos" => "Salvador-González" "email" => array:1 [ 0 => "bsalvador@ambitcp.catsalut.net" ] "referencia" => array:4 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">1</span>" "identificador" => "fn0005" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">2</span>" "identificador" => "fn0010" ] 3 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Jordi" "apellidos" => "Mestre-Ferrer" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">1</span>" "identificador" => "fn0005" ] ] ] 2 => array:3 [ "nombre" => "Maria" "apellidos" => "Soler-Vila" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">1</span>" "identificador" => "fn0005" ] ] ] 3 => array:3 [ "nombre" => "Luisa" "apellidos" => "Pascual-Benito" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">1</span>" "identificador" => "fn0005" ] ] ] 4 => array:3 [ "nombre" => "Eva" "apellidos" => "Alonso-Bes" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">1</span>" "identificador" => "fn0005" ] ] ] 5 => array:3 [ "nombre" => "Oriol" "apellidos" => "Cunillera-Puértolas" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">1</span>" "identificador" => "fn0005" ] ] ] 6 => array:2 [ "colaborador" => "on behalf of the research group of the MARREC-HTA project" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">3</span>" "identificador" => "fn0015" ] ] ] ] "afiliaciones" => array:6 [ 0 => array:3 [ "entidad" => "ABS Florida Sud, SAP Delta de Llobregat, DAP Costa de Ponent, Institut Català de la Salut, L’Hospitalet de Llobregat, Barcelona, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "ABS La Granja, Molins de Rei, SAP Baix Llobregat, DAP Costa de Ponent, Institut Català de la Salut, Molins de Rei, Barcelona, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "ABS Dr. Bartomeu Fabrés Anglada, SAP Delta de Llobregat, DAP Costa de Ponent, Institut Català de la Salut, Gavà, Barcelona, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "ABS Mas Font, SAP Delta de Llobregat, DAP Costa de Ponent, Institut Català de la Salut, Viladecans, Barcelona, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "ABS Gavà, SAP Delta de Llobregat, DAP Costa de Ponent, Institut Català de la Salut, Gavà, Barcelona, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Unidad de Soporte a la Investigación IDIAP J Gol, DAP Costa de Ponent, Institut Català de la Salut, Cornellà de Llobregat, Barcelona, Spain" "etiqueta" => "f" "identificador" => "aff0030" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "<span class="elsevierStyleItalic">Corresponding author</span>." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Enfermedad renal crónica en individuos hipertensos ≥60 años atendidos en Atención Primaria" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1217 "Ancho" => 1638 "Tamanyo" => 89287 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Estimation, based on the logistic regression model, of the probability of subjects included in the sample of hypertensive individuals aged ≥60 years, taken from the <span class="elsevierStyleItalic">SIDIAP plus</span> database as of 1st January 2011, being in the glomerular filtration rate <60 group, according to age and gender (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>73,730).</p> <p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Estimates for non-smokers with albumin/creatinine ratio <30<span class="elsevierStyleHsp" style=""></span>mg/dL, without dyslipidaemia, obesity, atrial fibrillation, heart failure or diabetes, living in an urban environment and in the central quintile of the MEDEA socioeconomic level. For any other individual profile, the expected probabilities according to the logistic regression model differ from those shown. However, the effect of the age-gender correlation shown is maintained.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Chronic kidney disease (CKD), defined as a reduction of the estimated glomerular filtration rate (eGFR) below 60<span class="elsevierStyleHsp" style=""></span>mL/min/1.73<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span> or the presence of kidney damage,<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">1</span></a> is associated with an increased risk of cardiovascular morbidity and mortality and progression to end-stage renal disease (ESRD) in both the general population and in hypertensive patients.<a class="elsevierStyleCrossRefs" href="#bib0170"><span class="elsevierStyleSup">2–5</span></a> Deaths from CKD increased by 82% worldwide between 1990 and 2010; this is the third uppermost increase out of the 25 leading causes of death after HIV/AIDS (396%) and diabetes (93%).<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">6</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Hypertension (HTN) is the second most common cause of ESRD. The number of cases of ESRD with a primary diagnosis of HTN is increasing, especially in the individulas >45 years, this is a consequence of greater survival rates in kidney failure patients and longer life expectancy.</p><p id="par0015" class="elsevierStylePara elsevierViewall">In hypertensive patients with CKD, blood pressure (BP) control is essential to minimise progression of CKD, reduce complications inherent to kidney failure and reduce the associated risk of cardiovascular disease.<a class="elsevierStyleCrossRefs" href="#bib0165"><span class="elsevierStyleSup">1,7,8</span></a> However, there is some debate about optimal values of BP. In the latest guidelines, the target BP of ≤130/80<span class="elsevierStyleHsp" style=""></span>mmHg has been limited to individuals with albuminuria of 30–300<span class="elsevierStyleHsp" style=""></span>mg/dL<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">1</span></a> or overt albuminuria,<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">7</span></a> while the target value of ≤140/90<span class="elsevierStyleHsp" style=""></span>mmHg has been maintained for the rest and, in some cases<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">8</span></a> for all hypertensive patients.</p><p id="par0020" class="elsevierStylePara elsevierViewall">Current recommendations for the diagnosis of CKD include standardised determination of creatinine and eGFR using the CKD-EPI formula.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">1</span></a> The CKD-EPI formula is more accurate at higher values of eGFR than previous formulas, and many studies have shown that it provides a lower estimate of the prevalence of CKD and a better prognostic classification.<a class="elsevierStyleCrossRefs" href="#bib0205"><span class="elsevierStyleSup">9–11</span></a> In Spain there are no studies in hypertensive patients using the above criteria.</p><p id="par0025" class="elsevierStylePara elsevierViewall">The objective of this study is to describe the prevalence and factors associated with a moderate decrease in eGFR (30–59 60<span class="elsevierStyleHsp" style=""></span>mL/min/1.73<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span>) estimated by CKD-EPI and to assess the degree of BP control in relation to wheter there is a reduction in eGFR, following the most recent recommendations for hypertensive patients aged ≥60 years, with no history of cardiovascular disease, treated in Primary Care Facilitites. This study is part of a cohort study primarily aiming to quantify the risk of cardiovascular events associated with a moderate decrease in eGFR and the progression of eGFR deterioration in relation to the degree of BP control in hypertensive individuals.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Material and methods</span><p id="par0030" class="elsevierStylePara elsevierViewall">This is a cross-sectional descriptive study. The data were obtained from the Information System for the Development of Research in Primary Care (SIDIAP), which contains clinical information about patients treated at the 274 primary healthcare centres of the Catalan Institute of Health (ICS) in Catalonia, which provides services to 5,835,000 patients (80% of the population). To ensure the quality of the data, a selected database, <span class="elsevierStyleItalic">SIDIAP plus</span><a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">12</span></a> was used which has shown to be valid and representative of the population for cardiovascular epidemiology studies.<a class="elsevierStyleCrossRef" href="#bib0225"><span class="elsevierStyleSup">13</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">We selected individuals aged ≥60 years included in the <span class="elsevierStyleItalic">SIDIAP plus</span> database since January 1st 2011, with a coded diagnosis of HTN (CIE10 codes: I10. I15 and subcategories) in the electronic primary care records, with a minimum follow up of 2 years, with measurement of standardised serum creatinine determination and BP at least once in the preceding 2 years, and with a maximum interval of 6 months. Exclusion criteria were: a) CKD stages 4 and 5 (eGFR<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>30<span class="elsevierStyleHsp" style=""></span>mL/min, dialysis or renal transplant); b) previous cardiovascular disease (myocardial infarction, angina, established or transient cerebrovascular accident, peripheral artery disease); and c) individuals included in a home care programme.</p><p id="par0040" class="elsevierStylePara elsevierViewall">Renal function was assessed using CKD-EPI,<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">9</span></a> without adjusting for race (not available), and KDIGO (Kidney Disease Improving Global Outcomes) classification.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">1</span></a> The last creatinine level and albumin/creatinine ratio (ACR), determined prior to 01/01/2011, were considered in each study subject. Covariables were: gender, age, rurality index (according to municipality of residence: urban if more than 10,000 inhabitants and population density >150<span class="elsevierStyleHsp" style=""></span>inhabitants/km<span class="elsevierStyleSup">2</span>, or rural if otherwise), socioeconomic deprivation index (MEDEA),<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">14</span></a> smoking habit, systolic (SBP) and diastolic (DBP) blood pressure, weight and height, glucose, total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, and coded diagnoses of heart failure (HF) and atrial fibrillation. As a criterion of contemporaneity, we considered the median of all determinations with a maximum interval of 6 months between them, as well as the median between the determinations and the relevant date of creatinine determination.</p><p id="par0045" class="elsevierStylePara elsevierViewall">The presence of cardiovascular risk factors was defined as: a) <span class="elsevierStyleItalic">diabetes mellitus</span> (DM): codes E11, E12, E14 and subcategories (2 determinations of fasting blood glucose >126<span class="elsevierStyleHsp" style=""></span>mg/dL or typical symptoms with random blood glucose >200<span class="elsevierStyleHsp" style=""></span>mg/dL); b) <span class="elsevierStyleItalic">hypercholesterolaemia</span>: total cholesterol >250<span class="elsevierStyleHsp" style=""></span>mg/dL or lipid-lowering drugs; c) <span class="elsevierStyleItalic">smoking habit</span>: smoker (daily consumption of one or more cigarettes during the last month, code F17), ex-smoker (more that 1 year with the diagnosis of smoker removed code Z72.0); and d) <span class="elsevierStyleItalic">obesity</span>: body mass index (BMI) ≥30<span class="elsevierStyleHsp" style=""></span>kg/m<span class="elsevierStyleSup">2</span>.</p><p id="par0050" class="elsevierStylePara elsevierViewall">BP levels ≤130/80<span class="elsevierStyleHsp" style=""></span>mmHg were considered adequate BP control in individuals with albuminuria (ACR<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>30<span class="elsevierStyleHsp" style=""></span>mg/dL), BP levels ≤140/90<span class="elsevierStyleHsp" style=""></span>mmHg were satisfactory for the remaining hypertensive patients.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">1</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">Information on pharmacological treatment was obtained from the pharmacy billing database, based on the ATC code of each active ingredient. The number of daily doses for each active ingredient taken from the pharmacy within ±6 months from the date of the baseline creatinine determination, with respect to the time interval between the first and last withdrawn was recorded. To estimate the level of exposure to each active ingredient, therapeutic compliance was defined as purchase of more than 60% of the total daily dose defined for the period. Administration of antihypertensive drugs affecting renal function (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, direct renin inhibitors, aldosterone antagonists and other diuretics) and other treatments that can modify cardiovascular risk (antiplatelet agents, lipid-lowering agents) was monitored.</p><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Statistical analysis</span><p id="par0060" class="elsevierStylePara elsevierViewall">Continuous variables were described as median and interquartile range, while qualitative variables were expressed as frequency and percentage.</p><p id="par0065" class="elsevierStylePara elsevierViewall">The Mann–Whitney <span class="elsevierStyleItalic">U</span>-test was used to compare quantitative variables and the chi-squared test for categorical variables between groups according to eGFR<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>60.</p><p id="par0070" class="elsevierStylePara elsevierViewall">Multivariate logistic regression models adjusted for variables with <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.10 in the bivariate analysis was used to determine the variables associated with eGFR<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>60 and the correlation of these with gender, age and DM. Any effects that detracted from the quality of the model were progressively eliminated according to the <span class="elsevierStyleItalic">Akaike Information Criteria</span>. The missing data were imputed according to the <span class="elsevierStyleItalic">Markov Chain Monte Carlo Multiple Imputation</span> method (5 imputations, 10 iterations; correlations included in the process). The resulting model was replicated without these data to observe the effect of data imputation.</p><p id="par0075" class="elsevierStylePara elsevierViewall">Statistics were calculated using R, version 2.14.2 (R Foundation for Statistical Computing, Vienna, Austria).</p><p id="par0080" class="elsevierStylePara elsevierViewall">The study was approved by the Independent Ethics Committee of the Jordi Gol Foundation for Primary Care Research (IDIAP).</p></span></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Results</span><p id="par0085" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a> shows the selection process flow chart for the 263,034 individuals aged ≥60 years with a diagnosis of HTN of 2 or more years of follow up included in the <span class="elsevierStyleItalic">SIDIAP plus</span> database as of 01/01/2011. The final study population included 73,730 individuals with a median age of 74 years, of whom 62.1% were women (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Prevalence of chronic kidney disease and associated factors</span><p id="par0090" class="elsevierStylePara elsevierViewall">In total, 18.8% of the study subjects presented with moderate CKD; in 72.2% of these, eGFR was between 45 and 59<span class="elsevierStyleHsp" style=""></span>mL/min. Prevalence was higher in women (19.9% in women versus 17.0% in men, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05) and increased with age, from 5.88% at 60–69 years to 39.4% in subjects >80 years. Individuals with decreased eGFR were older, with a higher percentage of women, from rural areas, diabetes mellitus, dyslipidaemia, HF and atrial fibrillation, a lower percentage of smokers/ex-smokers and obesity, and a lower socioeconomic level (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001), which increased significantly with the low eGFR level (global <span class="elsevierStyleItalic">p</span> and linear trend <0.001).</p><p id="par0095" class="elsevierStylePara elsevierViewall">Urinary ACR was available in 51.6% of the individuals (50.9% in the eGFR<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>60 group and 54.4% in the eGFR<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>60 group; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001), it was pathological in 13.1%. Supplementary Table 1 shows the descriptive data with imputations.</p><p id="par0100" class="elsevierStylePara elsevierViewall">A multivariate analysis to assess the variables associated with eGFR<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>60 showed that gender, age, HF, ACR<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>30<span class="elsevierStyleHsp" style=""></span>mg/dL, atrial fibrillation, smoking, dyslipidaemia, DM and obesity were significant factors (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>). Significant interactions were detected; the older the age of the patient, the weaker the correlation between male gender and eGFR<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>60 (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>). This correlation was inverted from the age of 80, when the risk of CKD was greater in women than in men. Correlation with age was similar for ACR<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>30<span class="elsevierStyleHsp" style=""></span>mg/dL and diagnosis of HF and DM. In men, the correlation between decreased eGFR and pathological ACR increased, whereas the correlation between decreased eGFR and DM, obesity and smoking habit decreased. In the case of DM, the risk was greater in the presence of obesity and lower in smokers and ex-smokers.</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0105" class="elsevierStylePara elsevierViewall">To observe the effect of imputations, the final multivariate model was replicated without them (Supplementary Table 2).</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Blood pressure and exposure to drugs</span><p id="par0110" class="elsevierStylePara elsevierViewall">The median SBP and DBP were 136 and 76<span class="elsevierStyleHsp" style=""></span>mmHg, respectively (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>). SBP did not differ significantly among individuals with and without decreased eGFR, but DBP was lower in the group with kidney disease (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001).</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0115" class="elsevierStylePara elsevierViewall">The level of BP control was 65.6% (66.5% in SBP and 94.6% in DBP). In individuals with decreased eGFR, BP control was lower overall and for SBP, and higher for DBP (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05).</p><p id="par0120" class="elsevierStylePara elsevierViewall">Exposure to antiplatelet, lipid-lowering and antihypertensive drugs was higher in hypertensive patients with CKD.</p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Discussion</span><p id="par0125" class="elsevierStylePara elsevierViewall">The prevalence of moderate CKD (eGFR 30–59<span class="elsevierStyleHsp" style=""></span>mL/min/1.73<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span>) in ≥60 years individuals, with HTN of more than 2 years and without cardiovascular disease, was 18.8%. It was associated with older age, male gender, HF, pathological ACR, atrial fibrillation, smoking, dyslipidaemia, DM and obesity. Percent of BP control (overall 65.6%) was slightly less in individuals with decreased eGFR.</p><p id="par0130" class="elsevierStylePara elsevierViewall">The prevalence of moderate CKD is comparable to that previously reported in hypertensive patients (17.2% in ≥55 years<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">15</span></a> and 21.8% in primary care in Italy<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">16</span></a>) and lower than that reported in Spain (from 24.4% to 27.4%,<a class="elsevierStyleCrossRefs" href="#bib0245"><span class="elsevierStyleSup">17–19</span></a> and as high as 50% in hypertensive women aged ≥65 years<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">20</span></a>). These differences may be due to the use of non-standardised creatinine determinations and to the calculating eGFR using the MDRD study equation, which underestimates eGFR at higher values, especially in young individuals and women,<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">9</span></a> as well as to the inclusion of individuals with previous cardiovascular disease associated with CKD.</p><p id="par0135" class="elsevierStylePara elsevierViewall">This study shows a strong positive correlation between older age and increased risk of decreased eGFR. This association has been widely described both in the general population<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">21</span></a> and in hypertensive individuals.<a class="elsevierStyleCrossRefs" href="#bib0235"><span class="elsevierStyleSup">15,16,18,19,22,23</span></a> In our study, age also affected other risk factors: the older the individual, the lesser the impact of male gender, pathological ACR, DM, atrial fibrillation and HF on CKD. This suggests that age predominates over the other risk factors in older individuals.</p><p id="par0140" class="elsevierStylePara elsevierViewall">The correlation observed between gender and CKD is similar to that described in the literature. The prevalence of CKD is generally higher in women,<a class="elsevierStyleCrossRefs" href="#bib0235"><span class="elsevierStyleSup">15–18,22</span></a> but when adjusted for other risk factors, male gender is associated with the presence of CKD<a class="elsevierStyleCrossRefs" href="#bib0215"><span class="elsevierStyleSup">11,24</span></a> and a greater risk of progression to ESRD.<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">25</span></a> The possibility that the eGFR equation is not correctly adjusted for age and gender cannot be ruled out. The CKD-EPI formula improves these aspects overall, compared with the MDRD study equation, but in the Three-city Prospective Cohort Study<a class="elsevierStyleCrossRef" href="#bib0290"><span class="elsevierStyleSup">26</span></a> in older individuals, CKD-EPI did not show superiority in identifying individuals with poor prognosis.</p><p id="par0145" class="elsevierStylePara elsevierViewall">In our analysis, pathological ACR was a risk factor for CKD, with more impact in men. Albuminuria is a known risk factor for CKD<a class="elsevierStyleCrossRefs" href="#bib0275"><span class="elsevierStyleSup">23,27</span></a> and progression to ESRD in hypertensive patients.<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">5</span></a> In this respect, it is important to emphasise that ACR determination was available in only half of all study cases, and showed a minimum increase in eGFR<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>60, despite the recommendations of clinical guidelines for the management of HTN<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">7</span></a> and CKD.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">1</span></a></p><p id="par0150" class="elsevierStylePara elsevierViewall">In this study, decreased eGFR was also significantly correlated with HF and, to a lesser degree, with atrial fibrillation. The correlation with HF,<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">24</span></a> left ventricular hypertrophy<a class="elsevierStyleCrossRefs" href="#bib0235"><span class="elsevierStyleSup">15,16,18</span></a> and cardiovascular disease<a class="elsevierStyleCrossRefs" href="#bib0235"><span class="elsevierStyleSup">15,16,18,20,22,28</span></a> has been described in other studies. HF is also a risk factor for CKD progression.<a class="elsevierStyleCrossRef" href="#bib0305"><span class="elsevierStyleSup">29</span></a></p><p id="par0155" class="elsevierStylePara elsevierViewall">The presence of other cardiovascular risk factors in hypertensive patients is known to increase the risk of CKD,<a class="elsevierStyleCrossRefs" href="#bib0255"><span class="elsevierStyleSup">19,20,27</span></a> and it is therefore considered a further manifestation of the atherosclerotic process. Smoking has been described as a predictor of albuminuria, especially in men, but not of eGFR<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>60.<a class="elsevierStyleCrossRefs" href="#bib0275"><span class="elsevierStyleSup">23,30</span></a> In our analysis, the increased risk of CKD associated with DM, obesity and smoking was lower in males. Interestingly, in the case of DM, the risk was greater in the presence of obesity and lower in smokers. All these effects may be assessed in greater detail in the follow-up of this cohort of hypertensive individuals aged ≥60 years.</p><p id="par0160" class="elsevierStylePara elsevierViewall">There is some debate about ideal BP levels, which have varied in recent years and making comparisons difficult. The 65.6% BP control obtained in our population is comparable to the 61.1% with <140/90 described in hypertensive patients seen in Primary Care,<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">31</span></a> while in individuals with CKD, 63.24% is comparable to the 60.2% described with the same criteria.<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">32</span></a> These percentages are much higher than those published in previous studies,<a class="elsevierStyleCrossRefs" href="#bib0270"><span class="elsevierStyleSup">22,23</span></a> and are in line with the improvement observed in the control of HTN in recent years<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">31</span></a> or in severe cases of HTN.<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">20</span></a> However, this improvement should be interpreted with caution, since individuals with no BP data over the study period were not included in our analysis. It should be emphasised that individuals with CKD have worse BP control, despite greater exposure to drugs. This situation, which has also been described in other studies,<a class="elsevierStyleCrossRefs" href="#bib0240"><span class="elsevierStyleSup">16,22,24</span></a> shows the difficulty involved in controlling BP in these individuals. Nevertheless, some degree of therapeutic inertia or failure to prioritise BP control in these at-risk individuals cannot be ruled out.</p><p id="par0165" class="elsevierStylePara elsevierViewall">The strength of this study is the large size of the population-based sample, which was taken from a validated and representative database used in cardiovascular epidemiology studies.<a class="elsevierStyleCrossRef" href="#bib0225"><span class="elsevierStyleSup">13</span></a> Creatinine determination, which was carried out in several laboratories, was performed according to standardised methods aligned with IDMS.</p><p id="par0170" class="elsevierStylePara elsevierViewall">Limitations of the study are its cross-sectional design, which prevents us from inferring causal associations. The results are representative of the hypertensive population without cardiovascular disease, treated and monitored in Primary Care. This population could possibly have a lower prevalence of decreased eGFR and better control of BP. The main objective of the project, of which this study is part, is to quantify the risk of cardiovascular events associated with a moderate decrease in eGFR. For this reason, individuals with previous cardiovascular disease were excluded, due to a higher incidence of new episodes and difficulties in distinguishing between new episodes and follow-up of previous ones using the data available in electronic medical records. BP records reflect standard clinical practice. As the specific circumstances of BP measurements are not recorded (single determination or the average of a series, rest conditions, etc.), the existence of heterogeneity among centres or professionals cannot be ruled out. The degree of BP control was not included in the multivariate analysis, because, in a cross-sectional study, it does not reflect the previous effect of BP on the presence of CKD. The analysis was performed using a single creatinine determination, which is common in epidemiological studies and also for ACR. Furthermore, data were not adjusted for race, because given the population characteristics in our setting, i.e., a clear predominance of Caucasians particularly in this age group, we believe this variable to be of little relevance. Finally, data for some variables were unavailable in many cases: regarding ACR, for example, as much as 48.8% of the data was missing. In these cases, the analysis of data without imputation could cause significant bias.</p><p id="par0175" class="elsevierStylePara elsevierViewall">Despite its obvious advantages, multiple imputation of missing data using the Markov Chain Monte Carlo methods is not without its limitations. First, such method assumes that the missing data are random, that is, that they can be explained without bias by the remaining variables collected. Second, the imputation method incorporates a variability associated with the unavailability of the observed data, so it is less likely to detect associations with imputed data than if all data were observed. However, the final multivariate model replicated without imputations yielded very similar results, the main differences being a greater association between decreased eGFR and the rest of the risk factors when excluding ACR and the non-attenuation of the DM risk in men.</p><p id="par0180" class="elsevierStylePara elsevierViewall">In conclusion, 1 out of 5 hypertensive individuals without cardiovascular disease, aged 60 or over and treated and monitored by Primary Care has a moderatedecreased eGFR, with albuminuria and HF as the main associated factors. Despite increased drug exposure, the control of BP control was poor in individuals with decreased eGFR. The follow-up of this cohort with and without moderately decreased eGFR will allow us to identify the factors associated with greater progression of kidney failure and incidence of cardiovascular events in our setting. Given the relevance of albuminuria in both the progression of CKD and cardiovascular risk, we believe that strategies to increase this determination in Primary Care should be explored, particularly in patients with kidney disease, and BP control should be prioritised and optimised in these individuals.</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Comments</span><p id="par0185" class="elsevierStylePara elsevierViewall">This study was carried out with anonymised data from Primary Care electronic medical records provided by SIDIAP (Information System for the Development of Research in Primary Care). To use these data, the project was evaluated by the Scientific Committee of SIDIAP and approved by the Independent Ethics Committee of the Jordi Gol Foundation for Primary Care Research (IDIAP).</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Funding</span><p id="par0190" class="elsevierStylePara elsevierViewall">This study was supported by a grant from <span class="elsevierStyleGrantSponsor" id="gs1">SIDIAP</span> (Information System for the Development of Research in Primary Care).</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Conflicts of interest</span><p id="par0195" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres889243" "titulo" => "Abstract" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Background" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Objectives" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Methods" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Results" ] 4 => array:2 [ "identificador" => "abst0025" "titulo" => "Conclusion" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec874965" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres889244" "titulo" => "Resumen" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "abst0030" "titulo" => "Antecedentes" ] 1 => array:2 [ "identificador" => "abst0035" "titulo" => "Objetivos" ] 2 => array:2 [ "identificador" => "abst0040" "titulo" => "Métodos" ] 3 => array:2 [ "identificador" => "abst0045" "titulo" => "Resultados" ] 4 => array:2 [ "identificador" => "abst0050" "titulo" => "Conclusiones" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec874964" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Material and methods" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Statistical analysis" ] ] ] 6 => array:3 [ "identificador" => "sec0020" "titulo" => "Results" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0025" "titulo" => "Prevalence of chronic kidney disease and associated factors" ] 1 => array:2 [ "identificador" => "sec0030" "titulo" => "Blood pressure and exposure to drugs" ] ] ] 7 => array:2 [ "identificador" => "sec0035" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0040" "titulo" => "Comments" ] 9 => array:2 [ "identificador" => "sec0045" "titulo" => "Funding" ] 10 => array:2 [ "identificador" => "sec0050" "titulo" => "Conflicts of interest" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2016-03-10" "fechaAceptado" => "2017-02-27" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec874965" "palabras" => array:5 [ 0 => "Chronic kidney disease" 1 => "Hypertension" 2 => "Primary Care" 3 => "Prevalence" 4 => "Risks factors" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec874964" "palabras" => array:5 [ 0 => "Enfermedad renal crónica" 1 => "Hipertensión arterial" 2 => "Atención Primaria" 3 => "Prevalencia" 4 => "Factores de riesgo" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Background</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Hypertension (HT) is the second leading cause of kidney failure. In hypertensive patients with chronic kidney disease (CKD), blood pressure (BP) control is the most important intervention to minimise progression. For CKD diagnosis, standardised creatinine and estimated glomerular filtration rate (eGFR) testing by CKD-EPI is recommended.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Objectives</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">To describe the prevalence and factors associated with a moderate decrease in eGFR (by CKD-EPI) and BP control in subjects with HT.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Methods</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Cross-sectional descriptive study in subjects ≥60 years included in the <span class="elsevierStyleItalic">SIDIAP plus</span> database with hypertension and standardised serum creatinine and BP tests in the last 2 years. Exclusion criteria: eGFR<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>30, dialysis or kidney transplantation, prior cardiovascular disease, home care. Primary endpoint: eGFR by CKD-EPI formula. Covariates: demographic data, examination, cardiovascular risk factors, heart failure and auricular fibrillation diagnosis, and drugs (antihypertensive agents acting on renal function, antiplatelet and lipid lowering agents). BP control criteria: ≤130/80<span class="elsevierStyleHsp" style=""></span>mmHg in individuals with albuminuria, ≤140/90 in all other subjects.</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Results</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Prevalence of eGFR <60<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>18.8%. Associated factors: age, gender, heart failure, albumin/creatinine ratio, auricular fibrillation, smoking, dyslipidaemia, diabetes and obesity. BP control: 66.14 and 63.24% in eGFR<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>60 and eGFR<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>60, respectively (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05). Exposure to drugs was higher in eGFR<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>60.</p></span> <span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Conclusion</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">One in 5 hypertensive patients without cardiovascular disease ≥60 years in primary care presented with a moderate decrease in eGFR. In addition to age and sex, albuminuria and heart failure were the main associated factors. Despite the increased exposure to drugs, BP control was lower in CKD.</p></span>" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Background" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Objectives" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Methods" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Results" ] 4 => array:2 [ "identificador" => "abst0025" "titulo" => "Conclusion" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "<span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Antecedentes</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">La hipertensión arterial (HTA) es la segunda causa de insuficiencia renal. En hipertensos con enfermedad renal crónica (ERC) el control de la presión arterial (PA) es la intervención más importante para minimizar la progresión. Para el diagnóstico de ERC se recomienda la determinación estandarizada de creatinina y filtrado glomerular estimado (FGe) según CKD-EPI.</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Objetivos</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Describir la prevalencia y los factores asociados a la disminución moderada del FGe (según CKD-EPI) y el control de PA en individuos con HTA.</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Métodos</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Estudio descriptivo transversal en individuos ≥60 años incluidos en la base de datos SIDIAP plus con HTA y registro de creatinina sérica estandarizada y PA en últimos 2<span class="elsevierStyleHsp" style=""></span>años. Criterios de exclusión: FGe<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>30, diálisis o trasplante renal, enfermedad cardiovascular previa, atención domiciliaria. Variable principal: FGe según CKD-EPI. Covariables: datos demográficos, exploración, factores de riesgo cardiovascular, diagnósticos de insuficiencia cardiaca y fibrilación auricular y fármacos (antihipertensivos con acción sobre función renal, antiagregantes, hipolipidemiantes). Criterio de control de la PA: ≤130/80<span class="elsevierStyleHsp" style=""></span>mmHg en individuos con albuminuria, ≤140/90 en el resto.</p></span> <span id="abst0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Resultados</span><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Prevalencia FGe<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>60: 18,8%. Factores asociados: edad, sexo, insuficiencia cardiaca, cociente albúmina/creatinina, fibrilación auricular, hábito tabáquico, dislipidemia, diabetes y obesidad. Control de la PA: 66,14 y 63,24% en FGe<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>60 y FGe<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>60 respectivamente (p<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0,05). La exposición a fármacos fue superior en FGe<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>60.</p></span> <span id="abst0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Conclusiones</span><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Uno de cada 5<span class="elsevierStyleHsp" style=""></span>hipertensos sin enfermedad cardiovascular ≥60 años en atención primaria presentó disminución moderada del FGe. Además de la edad y el sexo, la albuminuria y la insuficiencia cardiaca fueron los principales factores asociados. A pesar de la mayor exposición a fármacos, el control de la PA fue inferior en ERC.</p></span>" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "abst0030" "titulo" => "Antecedentes" ] 1 => array:2 [ "identificador" => "abst0035" "titulo" => "Objetivos" ] 2 => array:2 [ "identificador" => "abst0040" "titulo" => "Métodos" ] 3 => array:2 [ "identificador" => "abst0045" "titulo" => "Resultados" ] 4 => array:2 [ "identificador" => "abst0050" "titulo" => "Conclusiones" ] ] ] ] "NotaPie" => array:4 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Please cite this article as: Salvador-González B, Mestre-Ferrer J, Soler-Vila M, Pascual-Benito L, Alonso-Bes E, Cunillera-Puértolas O, et al. Enfermedad renal crónica en individuos hipertensos ≥60 años atendidos en Atención Primaria. Nefrologia. 2017;37:406–414.</p>" ] 1 => array:3 [ "etiqueta" => "1" "nota" => "<p class="elsevierStyleNotepara" id="npar0015">MACAP Renal. Research group recognised by the Generalitat of Catalonia (i.e., the local government of Catalonia) (SGR 2014-2016).</p>" "identificador" => "fn0005" ] 2 => array:3 [ "etiqueta" => "2" "nota" => "<p class="elsevierStyleNotepara" id="npar0020">MACAP Costa de Ponent. Jordi Gol Foundation for Primary Care Research (IDIAP).</p>" "identificador" => "fn0010" ] 3 => array:3 [ "etiqueta" => "3" "nota" => "<p class="elsevierStyleNotepara" id="npar0025">For members in MARREC-HTA project research group see <a class="elsevierStyleCrossRef" href="#sec0055">Appendix A</a>.</p>" "identificador" => "fn0015" ] ] "apendice" => array:1 [ 0 => array:1 [ "seccion" => array:1 [ 0 => array:4 [ "apendice" => "<p id="par0200" class="elsevierStylePara elsevierViewall">M. Jesús Cerain Herrero, Esther Freixes Villaró, Neus Gil Terrón, Mercedes Rodríguez Pascual, Laura Ruipérez Guijarro, Lluïsa Rodríguez Latre, Isabel Rosich Martí, Gemma Rodríguez Palomar, Jesús Almeda Ortega, Francisco Javier Tovillas Morán and Alberto Martínez Castelao.</p>" "etiqueta" => "Appendix A" "titulo" => "MARREC-HTA project research group" "identificador" => "sec0055" ] ] ] ] "multimedia" => array:5 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2273 "Ancho" => 1639 "Tamanyo" => 234112 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Selection process of the sample of individuals aged ≥60 years included in the <span class="elsevierStyleItalic">SIDIAP plus</span> database as of 1st January 2011, with a coded diagnosis of hypertension, a recent standardised serum creatinine determination and blood pressure measurement, and with no kidney failure, cardiovascular disease or home care.</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1217 "Ancho" => 1638 "Tamanyo" => 89287 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Estimation, based on the logistic regression model, of the probability of subjects included in the sample of hypertensive individuals aged ≥60 years, taken from the <span class="elsevierStyleItalic">SIDIAP plus</span> database as of 1st January 2011, being in the glomerular filtration rate <60 group, according to age and gender (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>73,730).</p> <p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Estimates for non-smokers with albumin/creatinine ratio <30<span class="elsevierStyleHsp" style=""></span>mg/dL, without dyslipidaemia, obesity, atrial fibrillation, heart failure or diabetes, living in an urban environment and in the central quintile of the MEDEA socioeconomic level. For any other individual profile, the expected probabilities according to the logistic regression model differ from those shown. However, the effect of the age-gender correlation shown is maintained.</p>" ] ] 2 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">ACR: urinary albumin/creatinine ratio; BMI: body mass index; DBP: diastolic blood pressure; SBP: systolic blood pressure.</p><p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">Numerical variables are shown with the overall median [1st quartile; 3rdquartile] according to the eGFR<span class="elsevierStyleInf">CKD-EPI</span> group, the <span class="elsevierStyleItalic">p</span>-value of the Kruskal–Wallis test of equal distribution of the variable according to the eGFRCKD-EPI group, and the p-value of the Spearman's rank correlation coefficient. Categorical variables are shown with the overall absolute frequency (relative frequency) according to the eGFR<span class="elsevierStyleInf">CKD-EPI</span> group, the p-value of the chi-squared test of equal distribution of the variable according to the eGFR<span class="elsevierStyleInf">CKD-EPI</span> group, and the <span class="elsevierStyleItalic">p</span>-value of the chi-squared linear trend test.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Overall <span class="elsevierStyleItalic">N</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>73,730 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">eGFR ≥ 60<br><span class="elsevierStyleItalic">N</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>59,863 (81.2%) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">eGFR 45–60<br><span class="elsevierStyleItalic">N</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>10,017 (13.6%) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">eGFR 30–44<br><span class="elsevierStyleItalic">N</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>3850 (5.22%) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Overall <span class="elsevierStyleItalic">p</span> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Trend <span class="elsevierStyleItalic">p</span> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">n</span> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">Age</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">74.0 (67.0; 80.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">72.0 (66.0; 78.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">79.0 (74.0; 84.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">82.0 (77.0; 86.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">73,730 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">Gender (female) n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">45,778 (62.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">36,670 (61.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6443 (64.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2665 (69.2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">73,730 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">Rurality n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7826 (10.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6284 (10.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1042 (10.4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">500 (13.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">73,706 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">MEDEA index</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.75 (0.15; 1.34) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.75 (0.16; 1.34) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.75 (0.13; 1.33) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.67 (0.07; 1.30) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">73,730 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="8" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">Smoking history n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">71,742 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Non-smoker \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">54,375 (75.8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">43,630 (74.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7713 (79.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3032 (81.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Smoker \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4943 (6.89) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4343 (7.45) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">436 (4.47) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">164 (4.42) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Ex-smoker \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">12,424 (17.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10,294 (17.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1615 (16.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">515 (13.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">BMI (kg/m</span><span class="elsevierStyleSup"><span class="elsevierStyleItalic">2</span></span><span class="elsevierStyleItalic">)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">29.4 (26.7; 32.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">29.5 (26.8; 32.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">29.3 (26.6; 32.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">29.0 (26.2; 32.4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">56,658 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">Blood glucose (mg/dL)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">101 (91.0; 120) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">101 (91.0; 120) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">100 (90.5; 118) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">100 (90.0; 119) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">73,232 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">Total cholesterol (mg/dL)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">205 (181; 229) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">206 (182; 230) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">201 (177; 226) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">199 (174; 224) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">72,558 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">Triglycerides (mg/dL)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">114 (86.5; 153) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">112 (85.0; 151) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">120 (91.0; 160) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">124 (95.0; 166) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">65,455 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">HDL cholesterol (mg/dL)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">53.0 (45.0; 63.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">54.0 (45.0; 63.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">52.0 (44.0; 62.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">51.0 (43.0; 61.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">65,649 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">LDL cholesterol (mg/dL)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">124 (104; 146) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">125 (104; 147) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">120 (100; 143) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">118 (97.0; 140) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">59,332 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">Creatinine (mg/dL)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.83 (0.70; 1.00) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.79 (0.69; 0.90) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1.07 (0.98; 1.22) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1.36 (1.21; 1.54) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">73,730 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">eGFR (mL/min/1.73</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">m</span><span class="elsevierStyleSup"><span class="elsevierStyleItalic">2</span></span><span class="elsevierStyleItalic">)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">78.3 (64.3; 88.2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">82.5 (72.6; 89.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">53.9 (50.0; 57.2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">39.6 (35.7; 42.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">73,730 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">ACR (mg/dL)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6.40 (3.70; 14.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6.00 (3.60; 12.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7.80 (4.00; 21.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">12.0 (5.30; 39.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">38,030 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">ACR > 30</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mg/dL</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4970 (13.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3272 (10.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1053 (19.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">645 (29.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">38,030 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">Diabetes mellitus n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">21,633 (29.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">17,306 (28.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3028 (30.2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1299 (33.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">73,730 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">Obesity n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">25,616 (45.2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">21,089 (45.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3336 (43.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1191 (41.8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">56,658 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">Hypercholesterolaemia n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">37,704 (51.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">30,353 (50.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5257 (52.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2094 (54.4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">73,730 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">Heart failure n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3111 (4.22) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1844 (3.08) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">779 (7.78) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">488 (12.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">73,730 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">Atrial fibrillation n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5127 (6.95) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3489 (5.83) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1120 (11.2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">518 (13.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">73,730 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1502155.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Characteristics of the sample of hypertensive individuals aged ≥60 years, in the total sample selected, according to eGFR<span class="elsevierStyleInf">CKD-EPI</span> ≥60, 45–59 or <30–44 (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>73,730), taken from the <span class="elsevierStyleItalic">SIDIAP plus</span> database as of 1 January 2011.</p>" ] ] 3 => array:7 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "<p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Model based on gender, age of 60 years, ACR, DM, dyslipidaemia, obesity, smoking habit, HF, AF, rurality(from rural areas), MEDEA and the correlation between these variables and gender, age and DM (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>73,730); final model presented as a result of the selection of variables using the Akaike Information Criteria; imputation of missing data.</p><p id="spar0095" class="elsevierStyleSimplePara elsevierViewall">95% CI: 95% confidence interval of OR; ACR: urinary albumin–creatinine ratio; AF: atrial fibrillation; DM: diabetes mellitus; HF: heart failure; OR: <span class="elsevierStyleItalic">odds ratio</span> calculated as the exponential of the coefficients of the model; <span class="elsevierStyleItalic">p</span>: <span class="elsevierStyleItalic">p</span>-value of the coefficient of the logistic regression model.</p><p id="spar0100" class="elsevierStyleSimplePara elsevierViewall">The correlations presented in the table start with a “-” sign and a “:” between the 2 correlated effects.</p><p id="spar0105" class="elsevierStyleSimplePara elsevierViewall">Model adjusted for rurality and age:obesity, age:AF, age:rurality and DM:AF correlations.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Model with ACR</th><th class="td" title="table-head " align="center" valign="top" scope="col"><span class="elsevierStyleItalic">p</span>-value \t\t\t\t\t\t\n \t\t\t\t</th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Coef. (Std Err.) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">OR (95% CI) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">(Intercept) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−3.691 (0.183) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Gender (male) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.421 (0.128) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.524 (1.186; 1.956) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Age \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.123 (0.009) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.130 (1.111; 1.151) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">ACR >30<span class="elsevierStyleHsp" style=""></span>mg/dL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.022 (0.117) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2.780 (2.205; 3.492) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">DM \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.030 (0.105) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.031 (0.839; 1.264) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.773 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Dyslipidaemia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.217 (0.033) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.242 (1.165; 1.325) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Obesity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.080 (0.097) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.083 (0.896; 1.310) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.409 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Smoker \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.354 (0.168) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.425 (1.017; 1.964) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.035 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Ex-smoker \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.278 (0.107) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.320 (1.067; 1.626) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.010 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">AF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.072 (0.195) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.074 (0.729; 1.568) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.714 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">HF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.362 (0.191) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3.906 (2.672; 5.656) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Rurality \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−0.145 (0.167) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.865 (0.628; 1.207) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.384 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">MEDEA quintile 2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.076 (0.065) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.079 (0.949; 1.226) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.246 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">MEDEA quintile 3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−0.027 (0.065) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.973 (0.857; 1.105) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.677 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">MEDEA quintile 4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.089 (0.063) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.093 (0.966; 1.237) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.158 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">MEDEA quintile 5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.089 (0.062) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.093 (0.968; 1.234) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.151 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-Gender (M): age \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−0.018 (0.005) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.983 (0.973; 0.992) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-Gender (M): ACR<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>30<span class="elsevierStyleHsp" style=""></span>mg/dL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.403 (0.084) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.496 (1.269; 1.765) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-Gender (M): DM \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−0.091 (0.080) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.913 (0.781; 1.068) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.255 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-Gender (M): obesity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−0.225 (0.069) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.799 (0.697; 0.915) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-Gender (M): smoker \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−0.431 (0.183) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.650 (0.456; 0.937) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.019 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-Gender (M): ex-smoker \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−0.270 (0.112) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.764 (0.614; 0.953) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.016 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-Gender (M): HF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−0.087 (0.115) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.917 (0.732; 1.147) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.448 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-Gender (M): MEDEA q 2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−0.080 (0.106) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.923 (0.751; 1.136) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.450 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-Gender (M): MEDEA q 3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−0.003 (0.106) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.997 (0.810; 1.227) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.979 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-Gender (M): MEDEA q 4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−0.158 (0.105) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.854 (0.695; 1.049) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.132 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-Gender (M): MEDEA q 5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−0.056 (0.104) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.946 (0.772; 1.159) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.592 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-Age: pathological ACR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−0.028 (0.006) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.972 (0.962; 0.983) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-Age: DM \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−0.007 (0.005) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.993 (0.984; 1.002) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.133 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-Age: dyslipidaemia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">– \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-Age: obesity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.002 (0.005) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.002 (0.993; 1.011) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.716 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-Age: HF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.006 (0.009) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.006 (0.989; 1.023) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.508 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-Age: HF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−0.040 (0.009) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.961 (0.944; 0.979) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-Age: rurality \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.011 (0.009) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.011 (0.994; 1.028) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.219 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-DM: obesity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.111 (0.066) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.117 (0.983; 1.270) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.091 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-DM: smoker \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−0.432 (0.159) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.649 (0.475; 0.885) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.007 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-DM: ex-smoker \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−0.101 (0.097) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.904 (0.748; 1.092) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.293 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">-DM: HF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.034 (0.109) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.035 (0.836; 1.281) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.754 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1502157.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Multivariate logistic regression model for eGFRCKD-EPI<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>60.</p>" ] ] 4 => array:7 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "<p id="spar0115" class="elsevierStyleSimplePara elsevierViewall">ACE inhibitors: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; BP: blood pressure; DBP: diastolic blood pressure; DRIs: dopamine reuptake inhibitors; SBP: systolic blood pressure.</p><p id="spar0120" class="elsevierStyleSimplePara elsevierViewall">Numerical variables are shown with the overall median [1st quartile; 3rdquartile] and according to the eGFR<span class="elsevierStyleInf">CKD-EPI</span> group, and the <span class="elsevierStyleItalic">p</span>-value of the Mann–Whitney <span class="elsevierStyleItalic">U</span>-test of equal distribution of the variable according to the eGFR<span class="elsevierStyleInf">CKD-EPI</span> group. Categorical variables are shown with the overall absolute frequency (relative frequency), according to the eGFR<span class="elsevierStyleInf">CKD-EPI</span> group, and the <span class="elsevierStyleItalic">p</span>-value of the chi-squared test of equal distribution of the variable according to the eGFRCKD-EPI group.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Overall <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">eGFR<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>60 <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">eGFR<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>60 <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">p</span> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">n</span></span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleBold">59,863 (81.2)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">n</span></span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleBold">13,867 (18.8)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">SBP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">136.00 (129.00; 143.50) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">136.00 (129.50; 143.50) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">136.00 (128.00; 144.00) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.165 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">DBP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">76.00 (70.00; 81.00) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">77.00 (70.50; 82.00) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">73.50 (68.00; 80.00) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">ACE inhibitors/ARBs/DRIs \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">50,187 (68.07) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">39,718 (66.35) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10,469 (75.50) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">BP control<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">48,365 (65.60) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">39,596 (66.14) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8769 (63.24) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">SBP control<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">48,992 (66.45) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">40,118 (67.02) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8874 (63.99) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">DBP control<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">69,758 (94.61) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">56,549 (94.46) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">13,209 (95.25) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Antiplatelets \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">13,099 (17.77) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">9807 (16.38) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3292 (23.74) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Lipid-lowering drugs \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">17,464 (23.69) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">13,874 (23.18) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3590 (25.89) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Diuretics \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">42,631 (57.82) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">33,352 (55.71) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">9279 (66.91) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Aldosterone antagonists \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">238 (0.32) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">150 (0.25) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">88 (0.63) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">ACE inhibitors \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">32,523 (44.11) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">26,074 (43.56) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6449 (46.51) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">ARA II \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">19,872 (26.95) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">15,312 (25.58) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4560 (32.88) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">DRIs \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">272 (0.37) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">192 (0.32) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">80 (0.58) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">ACE inhibitors/ARBs/DRIs \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">50,187 (68.07) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">39,718 (66.35) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10,469 (75.50) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1502156.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">SBP<span class="elsevierStyleHsp" style=""></span>≤<span class="elsevierStyleHsp" style=""></span>140 and DBP<span class="elsevierStyleHsp" style=""></span>≤<span class="elsevierStyleHsp" style=""></span>90 (SBP<span class="elsevierStyleHsp" style=""></span>≤<span class="elsevierStyleHsp" style=""></span>130 and DBP<span class="elsevierStyleHsp" style=""></span>≤<span class="elsevierStyleHsp" style=""></span>80 if albumin/creatinine ratio >30<span class="elsevierStyleHsp" style=""></span>mg/dL).</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0110" class="elsevierStyleSimplePara elsevierViewall">Blood pressure and exposure to drugs in the sample of hypertensive individuals aged ≥60 years, in the total sample selected, and according to eGFR<span class="elsevierStyleInf">CKD-EPI</span><span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>60 or ≥60 (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>73,730), taken from the <span class="elsevierStyleItalic">SIDIAP plus</span> database as of 1st January 2011.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:32 [ 0 => array:3 [ "identificador" => "bib0165" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "titulo" => "Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work GroupKDIGO clinical practice guideline for the evaluation and management of chronic kidney disease" ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Kidney Int Suppl" "fecha" => "2013" "volumen" => "3" "paginaInicial" => "1" "paginaFinal" => "150" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0170" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A.S. Go" 1 => "G.M. Chertow" 2 => "D. Fan" 3 => "CE HC McCulloch" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa041031" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2004" "volumen" => "351" "paginaInicial" => "1296" "paginaFinal" => "1305" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15385656" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0175" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Matsushita" 1 => "M. van der Velde" 2 => "B. Astor" 3 => "M. Woodward" 4 => "A. Levey" 5 => "P. de Jong" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(10)60674-5" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2010" "volumen" => "375" "paginaInicial" => "2073" "paginaFinal" => "2081" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20483451" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0180" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.T. Gansevoort" 1 => "K. Matsushita" 2 => "M. van der Velde" 3 => "B.C. Astor" 4 => "M. Woodward" 5 => "A.S. Levey" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/ki.2010.531" "Revista" => array:6 [ "tituloSerie" => "Kidney Int" "fecha" => "2011" "volumen" => "80" "paginaInicial" => "93" "paginaFinal" => "104" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21289597" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0185" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B.K. Mahmoodi" 1 => "K. Matsushita" 2 => "M. Woodward" 3 => "P.J. Blankestijn" 4 => "M. Cirillo" 5 => "T. Ohkubo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(12)61272-0" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2012" "volumen" => "380" "paginaInicial" => "1649" "paginaFinal" => "1661" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23013600" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0190" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Lozano" 1 => "M. Naghavi" 2 => "K. Foreman" 3 => "S. Lim" 4 => "K. Shibuya" 5 => "V. Aboyans" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(12)61728-0" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2012" "volumen" => "380" "paginaInicial" => "2095" "paginaFinal" => "20128" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23245604" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0195" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Mancia" 1 => "R. Fagard" 2 => "K. Narkiewicz" 3 => "J. Redon" 4 => "A. Zanchetti" 5 => "M. Böhm" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/eht151" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J" "fecha" => "2013" "volumen" => "34" "paginaInicial" => "2159" "paginaFinal" => "2219" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23771844" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0200" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "2014 USRDS annual data report: epidemiology of kidney disease in the United States" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "United States Renal Data System" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2014" "editorial" => "National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases" "editorialLocalizacion" => "Bethesda, MD" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0205" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A new equation to estimate glomerular filtration rate" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.S. Levey" 1 => "L.A. Stevens" 2 => "C.H. Schmid" 3 => "Y.L. Zhang" 4 => "A.F. Castro" 5 => "H.I. Feldman" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.7326/0003-4819-150-9-200905050-60000" "Revista" => array:6 [ "tituloSerie" => "Ann Intern Med" "fecha" => "2009" "volumen" => "150" "paginaInicial" => "604" "paginaFinal" => "612" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19414839" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0210" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical risk implications of the CKD epidemiology collaboration (CKD-EPI) equation compared with the Modification of Diet in Renal Disease (MDRD) study equation for estimated GFR" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "K. Matsushita" 1 => "M. Tonelli" 2 => "A. Lloyd" 3 => "A.S. Levey" 4 => "J. Coresh" 5 => "B.R. Hemmelgarn" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.ajkd.03.0162012" "Revista" => array:6 [ "tituloSerie" => "Am J Kidney Dis" "fecha" => "2012" "volumen" => "60" "paginaInicial" => "241" "paginaFinal" => "249" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22560843" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0215" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Enfermedad renal crónica en Atención Primaria: prevalencia y factores de riesgo asociados" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "B. Salvador González" 1 => "M. Rodríguez Pascual" 2 => "L. Ruipérez Guijarro" 3 => "A. Ferré González" 4 => "O. Cunillera Puertolas" 5 => "L.M. Rodríguez Latre" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.aprim.06.0032014" "Revista" => array:6 [ "tituloSerie" => "Aten Primaria" "fecha" => "2015" "volumen" => "47" "paginaInicial" => "236" "paginaFinal" => "245" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25212720" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0220" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. García-Gil" 1 => "E. Hermosilla" 2 => "D. Prieto-Alhambra" 3 => "F. Fina" 4 => "M. Rosell" 5 => "T. Williams" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Inform Prim Care" "fecha" => "2011" "volumen" => "19" "paginaInicial" => "135" "paginaFinal" => "145" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22688222" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0225" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Validity for use in research on vascular diseases of the SIDIAP (Information System for the Development of Research in Primary Care): the EMMA study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Ramos" 1 => "E. Ballo" 2 => "J. Marrugat" 3 => "R. Elosua" 4 => "J. Sala" 5 => "M. Grau" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.recesp.2011.07.017" "Revista" => array:6 [ "tituloSerie" => "Rev Esp Cardiol" "fecha" => "2012" "volumen" => "65" "paginaInicial" => "29" "paginaFinal" => "37" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22921172" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0230" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Construcción de un índice de privación a partir de datos censales en grandes ciudades españolas (Proyecto MEDEA)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.F. Dominguez-Berjón" 1 => "C. Borrell" 2 => "G. Cano-Serral" 3 => "S. Esnaola" 4 => "A. Nolasco" 5 => "M.I. Pasarín" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Gac Sanit" "fecha" => "2008" "volumen" => "22" "paginaInicial" => "179" "paginaFinal" => "187" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18405568" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0235" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the <span class="elsevierStyleItalic">Antihypertensive and lipid-lowering treatment to prevent heart attack trial</span>" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Rahman" 1 => "C.D. Brown" 2 => "J. Coresh" 3 => "B.R. Davis" 4 => "J.H. Eckfeldt" 5 => "N. Kopyt" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archinte.164.9.969" "Revista" => array:6 [ "tituloSerie" => "Arch Intern Med" "fecha" => "2004" "volumen" => "164" "paginaInicial" => "969" "paginaFinal" => "976" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15136305" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0240" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "CKD awareness and blood pressure control in the primary care hypertensive population" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Ravera" 1 => "G. Noberasco" 2 => "U. Weiss" 3 => "M. Re" 4 => "A.M. Gallina" 5 => "A. Filippi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.ajkd.08.0222010" "Revista" => array:6 [ "tituloSerie" => "Am J Kidney Dis" "fecha" => "2011" "volumen" => "57" "paginaInicial" => "71" "paginaFinal" => "77" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21087817" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0245" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalencia de enfermedad renal crónica en los hipertensos seguidos en los centros de salud de España y grado de control de su presión arterial (estudio DISEHTAE)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "L. Vara-González" 1 => "E. Martín Rioboó" 2 => "T. Ureña Fernández" 3 => "A. Dalfó Baqué" 4 => "I. Flor Becerra" 5 => "V. López Fernández" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1157/13120016" "Revista" => array:6 [ "tituloSerie" => "Atención Primaria" "fecha" => "2008" "volumen" => "40" "paginaInicial" => "241" "paginaFinal" => "245" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18482543" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0250" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Kidney function and cardiovascular disease in the hypertensive population: the ERIC-HTA study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Redón" 1 => "L. Cea-Calvo" 2 => "J.V. Lozano" 3 => "C. Fernández-Pérez" 4 => "J. Navarro" 5 => "A. Bonet" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/01.hjh.0000217848.10831.5f" "Revista" => array:6 [ "tituloSerie" => "J Hypertens" "fecha" => "2006" "volumen" => "24" "paginaInicial" => "663" "paginaFinal" => "669" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16531794" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0255" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: a 5693-patient cross-sectional analysis from Spain" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Gorostidi" 1 => "P. Sarafidis" 2 => "A. de la Sierra" 3 => "J. Segura" 4 => "J.J. de la Cruz" 5 => "J.R. Banegas" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.ajkd.2013.03.025" "Revista" => array:6 [ "tituloSerie" => "Am J Kidney Dis" "fecha" => "2013" "volumen" => "62" "paginaInicial" => "285" "paginaFinal" => "294" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23689071" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0260" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalencia de enfermedad renal crónica en mujeres hipertensas de edad avanzada atendidas en atención primaria. Estudio MERICAP" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J.L. Llisterri Caro" 1 => "V. Barrios Alonso" 2 => "A. de la Sierra Iserte" 3 => "C. Escobar Cervantes" 4 => "D. González-Segura Alsina" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.medcli.2011.03.038" "Revista" => array:5 [ "tituloSerie" => "Med Clin (Barc)" "fecha" => "2012" "volumen" => "138" "paginaInicial" => "512" "paginaFinal" => "518" ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0265" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence of chronic kidney disease in population-based studies: systematic review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Q-L. Zhang" 1 => "D. Rothenbacher" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1471-2458-8-117" "Revista" => array:5 [ "tituloSerie" => "BMC Public Health" "fecha" => "2008" "volumen" => "8" "paginaInicial" => "117" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18405348" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0270" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Función renal y riesgo cardiovascular en pacientes con hipertensión arterial esencial. Estudio FRESHA" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Herrero" 1 => "R. Marín" 2 => "F. Fernández Vega" 3 => "M. Gorostidi" 4 => "A. Riesgo" 5 => "J. Vázquez" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Nefrologia" "fecha" => "2006" "volumen" => "26" "paginaInicial" => "330" "paginaFinal" => "338" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16892821" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0275" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chronic kidney disease in hypertension under specialist care: the I-DEMAND study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Leoncini" 1 => "F. Viazzi" 2 => "E.A. Rosei" 3 => "E. Ambrosioni" 4 => "F.V. Costa" 5 => "G. Leonetti" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/HJH.0b013e328332038" "Revista" => array:6 [ "tituloSerie" => "J Hypertens" "fecha" => "2010" "volumen" => "28" "paginaInicial" => "156" "paginaFinal" => "162" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19915481" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0280" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence of kidney insufficiency in primary care population in Spain: EROCAP study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L.M. De Francisco a" 1 => "J.J. de la Cruz" 2 => "A. Cases" 3 => "M. de la Figuera" 4 => "M.I. Egocheaga" 5 => "J.I. Górriz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Nefrologia" "fecha" => "2007" "volumen" => "27" "paginaInicial" => "300" "paginaFinal" => "312" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17725449" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0285" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Left-ventricular hypertrophy and renal outcome in hypertensive patients in primary-care" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Ravera" 1 => "G. Noberasco" 2 => "A. Signori" 3 => "M. Re" 4 => "A. Filippi" 5 => "R. Cannavò" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/ajh/hps100" "Revista" => array:4 [ "tituloSerie" => "Am J Hypertens" "fecha" => "2013" "paginaInicial" => "700" "paginaFinal" => "777" ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0290" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epidemiology and prognostic significance of chronic kidney disease in the elderly: the three-city prospective cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B. Stengel" 1 => "M. Metzger" 2 => "M. Froissart" 3 => "M. Rainfray" 4 => "C. Berr" 5 => "C. Tzourio" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/ndt/gfr323" "Revista" => array:5 [ "tituloSerie" => "Nephrol Dial Transpl" "fecha" => "2011" "volumen" => "26" "paginaInicial" => "3286" "paginaFinal" => "3295" ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0295" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Urinary albumin excretion and glomerular filtration rate across the spectrum of glucose abnormalities in essential hypertension" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Redon" 1 => "F. Morales-Olivas" 2 => "A. Galgo" 3 => "M. Brito" 4 => "J. Mediavilla" 5 => "R. Marin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1681/ASN.2006080920" "Revista" => array:7 [ "tituloSerie" => "J Am Soc Nephrol" "fecha" => "2006" "volumen" => "17" "numero" => "Suppl. 3" "paginaInicial" => "S236" "paginaFinal" => "S245" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17130268" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0300" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Relation between abdominal obesity, insulin resistance and left ventricular hypertrophy diagnosed by electrocardiogram and magnetic resonance imaging in hypertensive patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.W. Vernooij" 1 => "M.J. Cramer" 2 => "F.L. Visseren" 3 => "M.J. Korndewal" 4 => "M.L. Bots" 5 => "M.F. Meijs" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.amjcard.2012.03.016" "Revista" => array:6 [ "tituloSerie" => "Am J Cardiol" "fecha" => "2012" "volumen" => "110" "paginaInicial" => "227" "paginaFinal" => "233" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22483385" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0305" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Association between chronic kidney disease progression and cardiovascular disease: results from the CRIC study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Rahman" 1 => "D. Xie" 2 => "H.I. Feldman" 3 => "A.S. Go" 4 => "J. He" 5 => "J.W. Kusek" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000368915" "Revista" => array:6 [ "tituloSerie" => "Am J Nephrol" "fecha" => "2014" "volumen" => "40" "paginaInicial" => "399" "paginaFinal" => "407" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25401485" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0310" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sex differences in hypertension-related renal and cardiovascular diseases in Italy: the I-DEMAND study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.L. Muiesan" 1 => "E. Ambrosioni" 2 => "F.V. Costa" 3 => "G. Leonetti" 4 => "A.C. Pessina" 5 => "M. Salvetti" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/HJH.0b013e328359b6a9" "Revista" => array:6 [ "tituloSerie" => "J Hypertens" "fecha" => "2012" "volumen" => "30" "paginaInicial" => "2378" "paginaFinal" => "2386" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23137952" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0315" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment and blood pressure control in Spain during 2002–2010" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.L. Llisterri" 1 => "G.C. Rodriguez-Roca" 2 => "C. Escobar" 3 => "F.J. Alonso-Moreno" 4 => "M. Prieto" 5 => "V. Barrios" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/HJH.0b013e3283592583" "Revista" => array:4 [ "tituloSerie" => "J Hypertens" "fecha" => "2012" "volumen" => "1" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/6681038" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0320" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Suboptimal blood pressure control in chronic kidney disease stage 3: baseline data from a cohort study in primary care" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.D. Fraser" 1 => "P.J. Roderick" 2 => "N.J. Mcintyre" 3 => "S. Harris" 4 => "C.W. Mcintyre" 5 => "R.J. Fluck" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1471-2296-14-88" "Revista" => array:5 [ "tituloSerie" => "BMC Fam Pract" "fecha" => "2013" "volumen" => "14" "paginaInicial" => "88" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23800117" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000003700000004/v1_201708310023/S201325141730127X/v1_201708310023/en/main.assets" "Apartado" => array:4 [ "identificador" => "38706" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003700000004/v1_201708310023/S201325141730127X/v1_201708310023/en/main.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S201325141730127X?idApp=UINPBA000064" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 10 | 12 | 22 |
2024 October | 72 | 57 | 129 |
2024 September | 90 | 36 | 126 |
2024 August | 93 | 68 | 161 |
2024 July | 111 | 40 | 151 |
2024 June | 107 | 55 | 162 |
2024 May | 94 | 33 | 127 |
2024 April | 95 | 36 | 131 |
2024 March | 85 | 24 | 109 |
2024 February | 51 | 40 | 91 |
2024 January | 50 | 21 | 71 |
2023 December | 50 | 27 | 77 |
2023 November | 73 | 36 | 109 |
2023 October | 54 | 22 | 76 |
2023 September | 51 | 23 | 74 |
2023 August | 67 | 43 | 110 |
2023 July | 62 | 23 | 85 |
2023 June | 72 | 23 | 95 |
2023 May | 83 | 154 | 237 |
2023 April | 59 | 22 | 81 |
2023 March | 124 | 28 | 152 |
2023 February | 129 | 15 | 144 |
2023 January | 105 | 32 | 137 |
2022 December | 95 | 32 | 127 |
2022 November | 117 | 32 | 149 |
2022 October | 112 | 48 | 160 |
2022 September | 84 | 41 | 125 |
2022 August | 65 | 52 | 117 |
2022 July | 67 | 50 | 117 |
2022 June | 76 | 54 | 130 |
2022 May | 115 | 33 | 148 |
2022 April | 147 | 57 | 204 |
2022 March | 165 | 64 | 229 |
2022 February | 104 | 55 | 159 |
2022 January | 90 | 45 | 135 |
2021 December | 105 | 40 | 145 |
2021 November | 62 | 44 | 106 |
2021 October | 93 | 46 | 139 |
2021 September | 73 | 52 | 125 |
2021 August | 46 | 35 | 81 |
2021 July | 38 | 37 | 75 |
2021 June | 29 | 21 | 50 |
2021 May | 50 | 45 | 95 |
2021 April | 113 | 102 | 215 |
2021 March | 76 | 25 | 101 |
2021 February | 48 | 61 | 109 |
2021 January | 54 | 22 | 76 |
2020 December | 57 | 12 | 69 |
2020 November | 50 | 20 | 70 |
2020 October | 34 | 20 | 54 |
2020 September | 55 | 19 | 74 |
2020 August | 43 | 28 | 71 |
2020 July | 42 | 18 | 60 |
2020 June | 53 | 22 | 75 |
2020 May | 60 | 21 | 81 |
2020 April | 43 | 18 | 61 |
2020 March | 46 | 17 | 63 |
2020 February | 62 | 23 | 85 |
2020 January | 75 | 27 | 102 |
2019 December | 76 | 28 | 104 |
2019 November | 77 | 24 | 101 |
2019 October | 106 | 25 | 131 |
2019 September | 46 | 17 | 63 |
2019 August | 34 | 21 | 55 |
2019 July | 40 | 28 | 68 |
2019 June | 39 | 33 | 72 |
2019 May | 47 | 18 | 65 |
2019 April | 68 | 18 | 86 |
2019 March | 54 | 46 | 100 |
2019 February | 44 | 29 | 73 |
2019 January | 31 | 33 | 64 |
2018 December | 167 | 52 | 219 |
2018 November | 389 | 21 | 410 |
2018 October | 328 | 26 | 354 |
2018 September | 116 | 23 | 139 |
2018 August | 85 | 72 | 157 |
2018 July | 62 | 15 | 77 |
2018 June | 66 | 20 | 86 |
2018 May | 69 | 18 | 87 |
2018 April | 162 | 16 | 178 |
2018 March | 105 | 23 | 128 |
2018 February | 173 | 8 | 181 |
2018 January | 74 | 14 | 88 |
2017 December | 176 | 5 | 181 |
2017 November | 76 | 12 | 88 |
2017 October | 64 | 12 | 76 |
2017 September | 60 | 15 | 75 |
2017 August | 62 | 14 | 76 |
2017 July | 21 | 5 | 26 |